| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA694: Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia |
|
Medicine details |
|
| Medicine name | bempedoic acid / ezetimibe (Nustendi®) |
| Formulation | 180 mg / 10 mg film-coated tablet |
| Reference number | 3888 |
| Indication | Treatment of adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet: in combination with a statin in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin in addition to ezetimibe, alone in patients who are either statin-intolerant or for whom a statin is contraindicated, and are unable to reach LDL-C goals with ezetimibe alone, in patients already being treated with the combination of bempedoic acid and ezetimibe as separate tablets with or without statin |
| Company | Daiichi Sankyo UK Ltd |
| BNF chapter | Cardiovascular system |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 02/07/2020 |
| NICE guidance | |
| Commercial arrangement | CAA |